10.1002/anie.201709532
Angewandte Chemie International Edition
COMMUNICATION
[17] A. E. Martell, R. M. Smith, in Crit. Stab. Constants Second Suppl.,
Springer, Boston, MA, 1989, pp. 1–66.
concentrated solutions of radionuclide. We anticipate that the
implementation of macropa-NCS will further advance the clinical
development of this important therapeutic radionuclide.
[18] S. L. Wu, W. D. Horrocks, J. Chem. Soc., Dalton Trans. 1997, 1497.
[19] R. D. Shannon, Acta Crystallogr. Sect. A 1976, 32, 751.
[20] M. Miederer, G. Henriksen, A. Alke, I. Mossbrugger, L. Quintanilla-
Martinez, R. Senekowitsch-Schmidtke, M. Essler, Clin. Cancer Res.
2008, 14, 3555.
Acknowledgements
[21] M. Essler, F. C. Gärtner, F. Neff, B. Blechert, R. Senekowitsch-
Schmidtke, F. Bruchertseifer, A. Morgenstern, C. Seidl, Eur. J. Nucl.
Med. Mol. Imaging 2012, 39, 602.
This work was supported by Cornell University and by a Pilot
Award from the Weill Cornell Medical College Clinical and
Translational Science Center, funded by NIH/NCATS
UL1TR00457. This research made use of the NMR Facility at
Cornell University, which is supported in part by the NSF under
award number CHE-1531632. TRIUMF receives funding via a
contribution agreement with the National Research Council of
Canada. We thank TRIUMF's ISAC facility for ion beam delivery
and Drs. Peter Kunz and Jens Lassen for help with collecting
225Ac and 225Ra samples. We also thank Dr. Eszter Boros at
Stony Brook University for providing us with trastuzumab, and Dr.
J. David Warren of the Milstein Core Chemistry Facility at Weill
Cornell Medicine for the use of equipment for analysis and
purification.
[22] W. F. Maguire, M. R. McDevitt, P. M. Smith-Jones, D. A. Scheinberg, J.
Nucl. Med. 2014, 55, 1492.
[23] M. Mato-Iglesias, A. Roca-Sabio, Z. Pálinkás, D. Esteban-Gómez, C.
Platas-Iglesias, É. Tóth, A. de Blas, T. Rodríguez-Blas, Inorg. Chem.
2008, 47, 7840.
[24] A. Roca-Sabio, M. Mato-Iglesias, D. Esteban-Gómez, É. Tóth, A. de
Blas, C. Platas-Iglesias, T. Rodríguez-Blas, J. Am. Chem. Soc. 2009,
131, 3331.
[25] R. Ferreirós-Martínez, D. Esteban-Gómez, É. Tóth, A. de Blas, C.
Platas-Iglesias, T. Rodríguez-Blas, Inorg. Chem. 2011, 50, 3772.
[26] M. P. Jensen, R. Chiarizia, I. A. Shkrob, J. S. Ulicki, B. D. Spindler, D. J.
Murphy, M. Hossain, A. Roca-Sabio, C. Platas-Iglesias, A. de Blas, et
al., Inorg. Chem. 2014, 53, 6003.
[27] A. E. Martell, R. M. Smith, Critical Stability Constants: Vol. 1, Plenum
Press, New York; London, 1974.
[28] M. Regueiro-Figueroa, J. L. Barriada, A. Pallier, D. Esteban-Gómez, A.
de Blas, T. Rodríguez-Blas, É. Tóth, C. Platas-Iglesias, Inorg. Chem.
2015, 54, 4940.
Keywords: actinides • actinium-225 • macrocyclic ligands •
radiopharmaceuticals • targeted alpha therapy
[29] M. G. Ferrier, E. R. Batista, J. M. Berg, E. R. Birnbaum, J. N. Cross, J.
W. Engle, H. S. La Pierre, S. A. Kozimor, J. S. Lezama Pacheco, B. W.
Stein, et al., Nat. Commun. 2016, 7, 12312.
[1]
M. R. Harrison, T. Z. Wong, A. J. Armstrong, D. George, Cancer Manag.
Res. 2013, 5, 1.
[30] M. G. Ferrier, B. W. Stein, E. R. Batista, J. M. Berg, E. R. Birnbaum, J.
W. Engle, K. D. John, S. A. Kozimor, J. S. Lezama Pacheco, L. N.
Redman, ACS Cent. Sci. 2017, 3, 176.
[2]
[3]
[4]
R. Coleman, Semin. Nucl. Med. 2016, 46, 99.
Y.-S. Kim, M. W. Brechbiel, Tumor Biol. 2012, 33, 573.
Y. Dekempeneer, M. Keyaerts, A. Krasniqi, J. Puttemans, S.
Muyldermans, T. Lahoutte, M. D’huyvetter, N. Devoogdt, Expert Opin.
Biol. Ther. 2016, 16, 1035.
[31] R. Ferreirós-Martínez, D. Esteban-Gómez, A. De Blas, C. Platas-
Iglesias, T. Rodríguez-Blas, Inorg. Chem. 2009, 48, 11821.
[32] G. J. Beyer, R. Bergmann, K. Schomäcker, F. Rösch, G. Schäfer, E. V
Kulikov, A. F. Novgorodov, Isot. Isot. Environ. Heal. Stud. 1990, 26, 111.
[33] M. M. Moasser, Oncogene 2007, 26, 6469.
[5]
[6]
E. W. Price, C. Orvig, Chem. Soc. Rev. 2014, 43, 260.
M. W. Geerlings, F. M. Kaspersen, C. Apostolidis, R. van der Hout,
Nucl. Med. Commun. 1993, 14, 121.
[34] B. Leyland-Jones, K. Gelmon, J.-P. Ayoub, A. Arnold, S. Verma, R.
Dias, P. Ghahramani, J. Clin. Oncol. 2003, 21, 3965.
[7]
M. R. McDevitt, D. Ma, L. T. Lai, J. Simon, P. Borchardt, R. K. Frank, K.
Wu, V. Pellegrini, M. J. Curcio, M. Miederer, et al., Science 2001, 294,
1537.
[35] D. Leveque, L. Gigou, J. P. Bergerat, Curr. Clin. Pharmacol. 2008, 3,
51.
[8]
[9]
M. Miederer, D. A. Scheinberg, M. R. McDevitt, Adv. Drug Deliv. Rev.
2008, 60, 1371.
[36] J. M. Kelly, A. Amor-Coarasa, A. Nikolopoulou, T. Wüstemann, P.
Barelli, D. Kim, C. Williams Jr., X. Zheng, C. Bi, B. Hu, et al., J. Nucl.
Med. 2017, 58, 1442.
D. A. Scheinberg, M. R. McDevitt, Curr. Radiopharm. 2011, 4, 306.
[10] Memorial Sloan Kettering Cancer Center, Targeted Atomic Nano-
Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal
Antibody HuM195) in Patients With Advanced Myeloid Malignancies.
ClinicalTrials.gov [website], Bethesda, MD: US National Library of
[37] A. P. Kozikowski, F. Nan, P. Conti, J. Zhang, E. Ramadan, T. Bzdega,
B. Wroblewska, J. H. Neale, S. Pshenichkin, J. T. Wroblewski, J. Med.
Chem. 2001, 44, 298.
[38] K. P. Maresca, S. M. Hillier, F. J. Femia, D. Keith, C. Barone, J. L. Joyal,
C. N. Zimmerman, A. P. Kozikowski, J. A. Barrett, W. C. Eckelman, et
al., J. Med. Chem. 2009, 52, 347.
Medicine.
NLM
identifier NCT00672165. Accessed Apr 20, 2017.
[11] I. A. Davis, K. A. Glowienka, R. A. Boll, K. A. Deal, M. W. Brechbiel, M.
Stabin, P. N. Bochsler, S. Mirzadeh, S. J. Kennel, Nucl. Med. Biol. 1999,
26, 581.
[39] S. M. Hillier, K. P. Maresca, F. J. Femia, J. C. Marquis, C. A. Foss, N.
Nguyen, C. N. Zimmerman, J. A. Barrett, W. C. Eckelman, M. G.
Pomper, et al., Cancer Res. 2009, 69, 6932.
[12] K. A. Deal, I. A. Davis, S. Mirzadeh, S. J. Kennel, M. W. Brechbiel, J.
Med. Chem. 1999, 42, 2988.
[40] J. A. Barrett, R. E. Coleman, S. J. Goldsmith, S. Vallabhajosula, N. A.
Petry, S. Cho, T. Armor, J. B. Stubbs, K. P. Maresca, M. G. Stabin, et
al., J. Nucl. Med. 2013, 54, 380.
[13] L. L. Chappell, K. A. Deal, E. Dadachova, M. W. Brechbiel, Bioconjug.
Chem. 2000, 11, 510.
[41] J. Kelly, A. Amor-Coarasa, A. Nikolopoulou, D. Kim, C. Williams Jr., S.
Ponnala, J. W. Babich, Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 647.
[42] A. Ghosh, W. D. W. Heston, J. Cell. Biochem. 2004, 91, 528.
[43] M. S. Dennis, M. Zhang, Y. Gloria Meng, M. Kadkhodayan, D.
Kirchhofer, D. Combs, L. A. Damico, J. Biol. Chem. 2002, 277, 35035.
[44] C. E. Dumelin, S. Trüssel, F. Buller, E. Trachsel, F. Bootz, Y. Zhang, L.
Mannocci, S. C. Beck, M. Drumea-Mirancea, M. W. Seeliger, et al.,
Angew. Chem. Int. Ed. 2008, 47, 3196.
[14] S. J. Kennel, L. L. Chappell, K. Dadachova, M. W. Brechbiel, T. K.
Lankford, I. A. Davis, M. Stabin, S. Mirzadeh, Cancer Biother.
Radiopharm. 2000, 15, 235.
[15] P. Comba, U. Jermilova, C. Orvig, B. O. Patrick, C. F. Ramogida, K.
Rück, C. Schneider, M. Starke, Chem.
- A Eur. J. 2017, DOI
10.1002/chem.201702284.
[16] M. R. McDevitt, D. Ma, J. Simon, R. K. Frank, D. A. Scheinberg, Appl.
Radiat. Isot. 2002, 57, 841.
This article is protected by copyright. All rights reserved.